Silo Pharma (SILO) said Wednesday that it has signed a service agreement with medical technology firm Resyca for a drug-device study of its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder, or PTSD.
Financial details were not disclosed.
Silo said the study is expected to provide the necessary device data and documentation for SPC-15's investigational new drug application, which the company plans to submit to the US Food and Drug Administration this year.
Silo is currently conducting two additional SPC-15 studies, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.